How should I evaluate and manage acute versus chronic urticaria, including medication choices, dosing, and referral criteria?

Evaluation and Management of Urticaria

Start all urticaria patients on a standard-dose second-generation H1-antihistamine immediately; for acute urticaria (<6 weeks) no laboratory testing is needed unless the history suggests a specific trigger, whereas chronic urticaria (≥6 weeks) that fails standard antihistamines requires a focused screening panel (CBC with differential, ESR or CRP, total IgE, and anti-thyroid peroxidase antibodies). 1

Clinical Classification and Initial Assessment

Duration-Based Classification

• Acute urticaria is defined as continuous activity lasting ≤6 weeks, while chronic urticaria persists ≥6 weeks—this temporal distinction fundamentally determines your diagnostic and therapeutic pathway. 2, 1
• Individual wheals in ordinary urticaria resolve within 2–24 hours without scarring; wheals persisting >24 hours are a red flag for urticarial vasculitis and mandate a lesional skin biopsy. 1, 3

Chronic Urticaria Subtypes

• Chronic spontaneous urticaria (CSU) presents with wheals and/or angioedema without identifiable triggers. 1
• Chronic inducible urticaria (CIndU) is reproducibly triggered by physical factors (cold, pressure, heat, dermographism, exercise); lesions typically fade within <1 hour except delayed-pressure urticaria, which appears 2–6 hours after stimulus and persists up to 48 hours. 1

Critical History Elements

• Ask: "Can you make your wheals appear?" to identify inducible urticaria requiring provocation testing. 1
• Review all medications—ACE inhibitors, ARBs, NSAIDs, and aspirin can trigger or aggravate urticaria. 1
• Inquire about systemic symptoms (fever, arthralgia, malaise) that suggest autoinflammatory syndromes. 1
• Request patient-taken photographs of lesions for longitudinal assessment. 1

Physical Examination

• Perform bedside dermographism testing by stroking the skin firmly with a tongue depressor. 1
• Assess for thyroid enlargement, lymphadenopathy, and other signs of systemic disease. 1

---

Diagnostic Workup

Acute Urticaria (<6 Weeks)

• No laboratory testing is required for typical acute urticaria unless the history points to a specific allergen. 1, 4
• IgE testing (skin prick or specific IgE) should be considered only when the history suggests particular allergens (latex, nuts, fish, shellfish). 1

Chronic Urticaria: Mild Disease (Controlled on Standard Antihistamines)

• No investigations are necessary if the patient achieves complete control with standard-dose second-generation H1-antihistamines. 1

Chronic Urticaria: Moderate-to-Severe or Antihistamine-Refractory

Obtain a focused screening panel: 1, 5

Test	Rationale
Complete blood count with differential	Detects eosinophilia (helminth infection) or leukopenia (systemic lupus erythematosus) [1]
ESR or CRP	Typically normal in CSU; elevation suggests urticarial vasculitis or autoinflammatory disease [1,3]
Total serum IgE	Low or very low levels indicate autoimmune chronic urticaria [1,5]
IgG anti-thyroid peroxidase (anti-TPO)	Positive in ≈14% of chronic urticaria patients vs ≈6% of controls [1,5]
Anti-TPO/total IgE ratio	High ratio is the most reliable surrogate marker for autoimmune CSU [1,5]

Red-Flag Scenarios Requiring Additional Testing

Wheals persisting >24 hours:

• Perform lesional skin biopsy to confirm or exclude urticarial vasculitis (look for leukocytoclasia, endothelial damage, fibrin deposition, red-cell extravasation). 1, 3
• If vasculitis is confirmed, order a full vasculitis screen including complement C3 and C4 to differentiate normocomplementemic from hypocomplementemic disease. 1, 3

Systemic symptoms (fever, arthralgia, malaise):

• Measure CRP and ESR (always elevated in autoinflammatory syndromes). 1, 3
• Screen for paraproteinemia in adults. 1
• Consider skin biopsy for neutrophil-rich infiltrates. 1
• Pursue genetic testing for hereditary periodic-fever syndromes when strongly suspected. 1

Isolated angioedema without wheals:

• First-line screening with serum C4 (low C4 has very high sensitivity for C1-inhibitor deficiency). 1, 5
• If C4 is low, confirm with quantitative and functional C1-inhibitor assays. 1, 5
• Test C1q and C1-inhibitor antibodies when acquired angioedema is suspected. 1
• Consider genetic analysis if laboratory results are normal but clinical suspicion persists. 1
• Review ACE-inhibitor exposure; discontinuation should lead to remission within days to 6 months. 1

Specialized Testing (Experienced Centers Only)

• The autologous serum skin test (ASST) provides reasonable sensitivity and specificity for detecting histamine-releasing autoantibodies, identifying roughly 30% of autoimmune chronic urticaria cases. 1, 5
• Provocation testing using standardized protocols (cold, pressure, dermographism, heat, exercise) is indicated when chronic inducible urticaria is suspected. 1

What NOT to Test

• Routine extensive laboratory panels are unnecessary in typical chronic urticaria. 1
• Skin-prick or specific-IgE testing is not indicated unless the history suggests a discrete allergen trigger. 1
• Screening for occult infections (dental abscess, gastrointestinal candidiasis) lacks supporting evidence. 1
• Routine malignancy screening is not recommended; epidemiologic data show no association between chronic urticaria and cancer. 1

---

Treatment Algorithm

Step 1: First-Line Treatment (All Urticaria)

• Start with a standard-dose second-generation H1-antihistamine (cetirizine, loratadine, fexofenadine, desloratadine). 2, 1
• This achieves adequate control in approximately 40% of patients. 1
• For children, verify age-specific dosing against the product data sheet; no licensed H1-antihistamine is contraindicated in children ≥12 years, but for younger children the choice must be individualized based on product labeling. 1

Step 2: Dose Escalation (If Inadequate Control After 2–4 Weeks)

• Increase the second-generation H1-antihistamine dose up to 4-fold above the standard dose. 2, 1
• This off-license use is supported by international guidelines and is safe in both adults and children. 2, 1

Step 3: Add-On Omalizumab (Second-Line for Chronic Urticaria)

• If symptoms remain inadequately controlled on high-dose antihistamines, add omalizumab 300 mg subcutaneously every 4 weeks. 2
• In patients with insufficient response, consider updosing by shortening the interval and/or increasing the dosage; the maximum recommended dose is 600 mg every 2 weeks. 2
• Allow up to 6 months for patients to respond to omalizumab. 2
• The risk-benefit profile of high-dose omalizumab is superior to that of cyclosporine. 2

Step 4: Add-On Cyclosporine (Third-Line for Chronic Urticaria)

• For patients who do not respond to higher-than-standard doses of omalizumab, consider cyclosporine up to 5 mg/kg body weight. 2, 3
• Monitor blood pressure and renal function (BUN and creatinine) every 6 weeks while on cyclosporine. 2
• Potential risks include hypertension, epilepsy in predisposed individuals, hirsutism, gum hypertrophy, and renal failure. 2

Adjunctive Therapies

H2-antihistamines:

• Adding an H2-antihistamine (ranitidine or cimetidine) to an H1-blocker may improve control, especially for symptomatic dermographism. 1

Sedating antihistamines:

• A sedating antihistamine at bedtime can control nocturnal itching when needed. 1

Leukotriene receptor antagonists:

• In a small subgroup of chronic urticaria patients, montelukast may provide additional benefit. 1

Short-course systemic corticosteroids:

• Reserve oral corticosteroids for severe acute urticaria or angioedema involving the oral cavity; use a brief course (adult dose: 50 mg/day for 3 days; lower dose for children). 1
• Long-term corticosteroid therapy is discouraged; it should be limited to cases of delayed-pressure urticaria or urticarial vasculitis under specialist supervision. 1, 3

Topical symptomatic relief:

• 1% menthol in aqueous cream or calamine lotion provides antipruritic relief. 1

Step-Down Protocol

• In patients with complete disease control (Urticaria Control Test score >16), consider step-down to reduce treatment burden and assess for spontaneous remission. 2
• Patients should not step down a higher-than-standard-dosed antihistamine before completing at least 3 consecutive months of complete control. 2
• Reduce the daily dose by no more than 1 tablet per month. 2
• When control is lost during step-down, return to the last dose that provided complete control. 2

---

Disease Activity Monitoring

• At every visit, use the 7-Day Urticaria Activity Score (UAS7) (range 0–42), which combines daily wheal count (0–3) and itch severity (0–3) for each of seven days. 1
• Use the Urticaria Control Test (UCT) to guide decisions on treatment escalation. 2, 1
• Therapeutic decisions should be based on these disease-control measurements rather than merely on the presence of symptoms. 1

---

Referral Criteria

Refer to Allergist-Immunologist When:

• Acute urticaria or angioedema occurs without an obvious or previously defined trigger after a severe allergic reaction. 2
• Acute urticaria or angioedema is caused by a presumed food or drug requiring diagnostic confirmation or assistance with avoidance procedures. 2
• Chronic urticaria or angioedema persists (lesions recurring over ≥6 weeks). 2
• Chronically recurring angioedema occurs without urticaria (may indicate hereditary or acquired angioedema, paraproteinemia, or B-cell malignancies). 2
• Suspected or proved cutaneous or systemic mastocytosis. 2

Refer to Dermatology or Rheumatology When:

• Lesions last >24 hours, leave ecchymotic/purpuric/hyperpigmented residua, or are associated with pain or burning (urticarial vasculitis). 2, 3
• Typical urticaria-angioedema with signs and symptoms suggestive of systemic illness. 2
• Symptom control requires regular steroid use. 2
• Suspected urticarial vasculitis requires rheumatology evaluation for systemic lupus erythematosus overlap and management of joint or systemic manifestations. 3

---

Emergency Management

Laryngeal Angioedema or Anaphylaxis

• Administer immediate intramuscular epinephrine. 1
• For children weighing 15–30 kg, use a 150 µg epinephrine autoinjector. 1
• If there is no significant improvement after the first injection, administer a second dose promptly. 1
• Parenteral hydrocortisone may be added as an adjunct for severe laryngeal edema (recognizing its delayed onset of action). 1
• Prescribe a home epinephrine autoinjector for any patient with a history indicating risk of recurrent life-threatening attacks. 1

Hereditary Angioedema (HAE)

• Antihistamines, systemic corticosteroids, and epinephrine are ineffective for HAE because the edema is mediated by bradykinin rather than histamine. 5
• First-line on-demand therapies include plasma-derived C1-inhibitor concentrate, icatibant (bradykinin-B2 receptor antagonist), and ecallantide (plasma kallikrein inhibitor). 5
• In airway emergencies, administer C1-inhibitor concentrate at 20 U/kg and prepare for possible endotracheal intubation. 5

---

Trigger Avoidance and Lifestyle Modifications

• Systematic identification and elimination of specific triggers improves outcomes in >40% of pediatric cases. 1
• NSAIDs and aspirin provoke mast-cell degranulation and should be avoided. 1
• Physical triggers (overheating, emotional stress, alcohol, cold, pressure, exercise, heat) should be minimized. 1

---

Common Pitfalls

• Do not order extensive laboratory testing for typical acute urticaria; it adds no clinical value and is not cost-effective. 1, 4
• Do not assume all angioedema is histamine-mediated; bradykinin-mediated forms (ACE-inhibitor-induced, hereditary angioedema) require distinct management and do not respond to antihistamines. 1, 5
• Do not delay skin biopsy when wheals persist >24 hours; urticarial vasculitis necessitates different therapy and carries a poorer prognosis. 1, 3
• Avoid long-term oral corticosteroids; they are reserved only for selected severe cases under specialist supervision. 1, 3

---

Prognosis

• In acute urticaria, ≈50% of children presenting with wheals alone achieve remission within 6 months. 1
• Children with chronic urticaria and angioedema have a poorer outlook, with >50% maintaining active disease beyond 5 years. 1
• Despite thorough evaluation, a substantial proportion of chronic urticaria cases remain idiopathic, reflecting current knowledge limits rather than diagnostic failure. 1, 4